Safety & Immunogenicity Study of Ad5 Based Oral Norovirus Vaccines

NCT03897309 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

86

Enrollment

INDUSTRY

Sponsor class

Conditions

Norovirus Infection

Interventions

BIOLOGICAL: VXA-G1.1-NN
BIOLOGICAL: VXA-G2.4-NS
BIOLOGICAL: Placebo Tablets

Sponsor

Vaxart